Highlights Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
22.35 ^USD	-1.80%		-3.50%	+16.77%

May. 31	Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	MT
May. 31	Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	May. 31	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	May. 31	MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications	May. 30	CI
Sector Update: Health Care Stocks Softer Late Afternoon	May. 08	MT
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue	May. 08	MT
Eurobio Scientific: agreement with Myriad Genetics	May. 08	CF
Eurobio Scientific to Buy Gene Expression Test for Breast Cancer	May. 08	MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M	May. 07	MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05	May. 07	MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M	May. 07	MT
Myriad Genetics to Seek Acquisitions	May. 07	CI
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 07	CI
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million.	May. 06	CI
Myriad Genetics Gets US Patent for SneakPeek Snap Device	Mar. 20	MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	Feb. 27	MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	Feb. 27	MT
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	Feb. 27	CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Highlights

Filters